In a Bad Year for Biotech Stocks, Deals and Vaccines Were Winners – The Wall Street Journal

Biotech stocks have crumbled this year and a number of prominent hedge funds have suffered deep losses.

But some biotech investors are thriving by focusing on mergers, short selling and Covid-19 stocks. Some analysts and investors say these three strategies will prove successful for biotech investors once again in 2022.

Leave a comment

Your email address will not be published. Required fields are marked *